Khaitan & Co  and Cyril Amarchand Mangaldas are advising Indian drugmaker Gland Pharma on its planned $780 million IPO, with Herbert Smith Freehills and S&R Associates acting for the bookrunners and lead managers.

The Hyderabad-headquartered Gland Pharma, a subsidiary of China’s Fosun Pharmaceutical, is a major supplier of API heparin to hospitals in India. Its IPO will make it the first Indian company with a Chinese parent to list its equity shares on an Indian stock exchange.

The bookrunning lead managers are Kotak Mahindra Capital, Citigroup Global Markets India, Haitong Securities India and Nomura India.

The Khaitan team is being led by partners Abhimanyu Bhattacharya, Aditya Cheriyan, Niren Patel and Vivek Sriram.


To contact the editorial team, please email